Epstein-Barr virus BZLF1 peptide–Major Histocompatibility Complex (EBV BZLF1-MHC)

The Epstein-Barr virus (EBV) BZLF1 peptide–Major Histocompatibility Complex (MHC) is a cell-surface molecular target found on cells undergoing the lytic phase of EBV infection (Source: UniProt P03206). BZLF1, also known as Zta or ZEBRA, is an immediate-early transcription factor that triggers the transition from viral latency to lytic replication (Source: PubMed 8144874). Fragments of the BZLF1 protein are processed by the cellular proteasome and loaded onto MHC Class I molecules for presentation to the immune system. These complexes are primarily recognized by CD8+ cytotoxic T cells, making them a focal point for natural antiviral immunity and a high-priority target for adoptive cell therapies (Source: PubMed 30305453). In clinical applications, engineered T-cell receptors (TCRs) and TCR-like antibodies are designed to bind these specific peptide-MHC combinations to treat EBV-associated malignancies, such as post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma (Source: Atara Biotherapeutics). Targeting BZLF1 is particularly advantageous because it is expressed very early in the lytic cycle, potentially allowing for the elimination of infected cells before the release of new viral particles. Therapeutic strategies often focus on immunodominant epitopes, such as the RAKFKQLL peptide presented by HLA-A*02:01 (Source: PubMed 8144874).

Other names

EBV Zta-MHC complexEBV ZEBRA-MHC complexBZLF1-HLA complexHLA-BZLF1 antigenRAKFKQLL-HLA-A*02:01 complexEpstein-Barr virus immediate-early protein-MHC

T-cell receptor (TCR) mediated recognition and subsequent cytotoxic lysis of EBV-infected cells presenting BZLF1 peptides on MHC Class I molecules.